Should we continue or stop insulin sensitizing drugs during pregnancy?
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: The use of insulin sensitizing drugs such as metformin in polycystic ovary syndrome has been increasingly popular and validated by systematic reviews. There has also been an interest in the use of metformin for gestational diabetes. However, administration of metformin to prevent miscarriage is controversial and widespread use of this drug in early pregnancy requires investigation. RECENT FINDINGS: There are claims that miscarriage and gestational diabetes are more common in polycystic ovary syndrome and that use of insulin sensitizers improves outcomes dramatically. This review suggests there is no evidence for increased risk of miscarriage solely due to polycystic ovary syndrome and that there are insufficient data for promoting therapy with metformin. There is some reason for use of metformin in mid-pregnancy for gestational diabetes but better evidence from randomized controlled trials is urgently needed. SUMMARY: The use of metformin in early pregnancy for reducing the risk of miscarriage should be avoided outside of the context of properly designed prospective randomized trials. Safety in early pregnancy appears to be reassuring but not completely proven. The use of metformin in mid-pregnancy for gestational diabetes appears more logical but also needs adequate trials before general use is advocated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Kiddy, D. S., Hamilton‐Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M. J., & Franks, S. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02909.x · Cited by 921
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786
Self-citationSalpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.21.2594 · Cited by 312
Costello, M. F., & Eden, J. A. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04554-5 · Cited by 224
Polycystic ovaries and recurrent miscarriage—a reappraisal
Rai, R., Backos, M., Rushworth, F., & Regan, L. (2000) · Human Reproduction · doi:10.1093/humrep/15.3.612 · Cited by 215
Cited by
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS)
Siddiqui, S., Mateen, S., Ahmad, R., & Moin, S. (2022) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-022-02625-7 · Cited by 347
Palomba, S., Orio, F., Falbo, A., Manguso, F., Russo, T., Cascella, T., Tolino, A., Carmina, E., Colao, A., & Zullo, F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0110 · Cited by 279
Metformin vs insulin in the management of gestational diabetes: a meta-analysis
Gui, J., Liu, Q., & Feng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064585 · Cited by 222
“However, insulin has several disadvantages including multiple daily injections, the risk of hypoglycemia and maternal weight gain [15].”
Background
Metadata
- Authors
- Norman, R. J., Wang, J. X., & Hague, W.
- Venue
- Current Opinion in Obstetrics and Gynecology
- Published
- 2004-06
- Volume
- 16
- Issue
- 3
- Pages
- 245-250
- ISSN
- 1040-872X (ISSN-L)
- OpenAlex
- W2048527301
- Cited by
- 71
- References
- 6
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Should we continue or stop insulin sensitizing drugs during pregnancy? https://app.cochat.ai/papers/10.1097/00001703-200406000-00007
- The paper
- Norman, R. J., Wang, J. X., & Hague, W. (2004). Should we continue or stop insulin sensitizing drugs during pregnancy? Current Opinion in Obstetrics and Gynecology. https://doi.org/10.1097/00001703-200406000-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.